Roumen Balabanov to Multiple Sclerosis
This is a "connection" page, showing publications Roumen Balabanov has written about Multiple Sclerosis.
Connection Strength
1.397
-
Molecular mechanisms of oligodendrocyte injury in multiple sclerosis and experimental autoimmune encephalomyelitis. Int J Mol Sci. 2012; 13(8):10647-10659.
Score: 0.359
-
Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-World, Open-Label Study. CNS Drugs. 2022 09; 36(9):977-993.
Score: 0.180
-
Repurposing the cardiac glycoside digoxin to stimulate myelin regeneration in chemically-induced and immune-mediated mouse models of multiple sclerosis. Glia. 2022 10; 70(10):1950-1970.
Score: 0.178
-
ZEB1 promotes pathogenic Th1 and Th17 cell differentiation in multiple sclerosis. Cell Rep. 2021 08 24; 36(8):109602.
Score: 0.168
-
Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study. Adv Ther. 2021 07; 38(7):3724-3742.
Score: 0.165
-
Treatment of natalizumab-associated PML with filgrastim. Ann Clin Transl Neurol. 2019 May; 6(5):923-931.
Score: 0.142
-
Interferon regulatory factor 1 regulation of oligodendrocyte injury and inflammatory demyelination. Rev Neurosci. 2012 Jan 26; 23(2):145-52.
Score: 0.086
-
IRF-1 signaling in central nervous system glial cells regulates inflammatory demyelination. J Neuroimmunol. 2011 Apr; 233(1-2):147-59.
Score: 0.080
-
IL-12 p40 monomer is different from other IL-12 family members to selectively inhibit IL-12R?1 internalization and suppress EAE. Proc Natl Acad Sci U S A. 2020 09 01; 117(35):21557-21567.
Score: 0.039